2016 American Transplant Congress
Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data.
Background: While modern immunosuppressive therapies (ISx) have substantially reduced acute rejection, ISx medications have many side effects, and transplant recipients must take an array of…2016 American Transplant Congress
Sociodemographic and Comorbidity Differences Between Dialysis, Waitlisted and Transplant Patients in the UK: Findings from the ATTOM Study.
IntroductionAccess to Transplantation and Transplant Outcome Measures (ATTOM) is a prospective cohort study involving all 72 UK renal units, investigating factors affecting access to and…2016 American Transplant Congress
The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation.
CMV-seronegative kidney transplant recipients (KTRs) from CMV-seropositive donors are at highly increased risk of primary CMV-infection with associated inferior outcomes after kidney transplantation. Presence of…2016 American Transplant Congress
Graft Outcomes in Pediatric Kidney Transplants Are Better with Laparoscopic Donor Nephrectomy and High Volume Centers.
1Abdominal Organ Transplantation, OHSU, Portland, OR; 2Urology, OHSU, Portland, OR.
Purpose Initial reports for pediatric kidney recipients suggested superior outcomes for open donor (ODN) compared to laparoscopic donor nephrectomy (LDN). Current outcomes based on donor…2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…2016 American Transplant Congress
Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years.
Medicine, University of Florida, Gainesville, FL.
BACKGROUND: There is no published study comparing the significance of risk factors for graft outcomes associated with common induction regimens combined with tacrolimus and mycophenolate…2016 American Transplant Congress
DAAs Rapidly Clear HCV Viremia in Recipients of HCV+ Donor Kidneys.
Purpose: Direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C (HCV) in both general and liver transplant populations. However, data in kidney transplant…2016 American Transplant Congress
Wait List Removals and Transplant Rates Are Significantly Associated with Transplant Center Performance Oversight.
Cleveland Clinic, Cleveland, OH.
Prior studies indicate that low performance(LP) center evaluations by the SRTR are associated with reductions in transplant volume. There is limited information to determine whether…2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…2016 American Transplant Congress
Living Donor Kidney Transplant Outcomes Have Improved Over the Last Decade.
Medicine, University of Virginia, Charlottesville, VA.
Our group recently reported improved 6-month eGFR and long-term patient and allograft outcomes in deceased donor transplant over the last decade. Our goal was to…
- « Previous Page
- 1
- …
- 432
- 433
- 434
- 435
- 436
- …
- 531
- Next Page »